NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Centre Hospitalier Universitaire de Nice
Conditions: Multiple Sclerosis, Radiologically Isolated Syndrome, Epstein-Barr Virus
Interventions: NO INTERVENTION
Countries: France
The clinical course of RRMS patients is variable. Among RIS-Consortium international cohorts, one third of RIS patients progressed to MS at 5 years and 52.2% at 10 years. Biomarkers predictive of MS conversion are key elements to organize personalized medical care, for both follow-up and treatment strategies. EBV seems to be an interesting candidate regarding its involvement MS pathophysiology. It can be easily assess in blood sample in contrast to others prognostic biomarkers validated in RIS : oligoclonal bands and NfL levels in cerebrospinal fluid and serum. In RIS, treatment targeting EBV could significantly modify the course of the disease. The investigators aim to make the fisrt description of the EBV epidemiology (immunoglobulin (Ig)M and IgG anti-viral capsid antigen (VCA), IgG anti Epstein-Barr nuclear antigen (EBNA)) among RIS patients and to investigate a correlation between the different antibodies' titers (IgM VCA, IgG VCA, IgG EBNA) and the course of the disease (clinical conversion or evidence of disease activity (EDA)).
Sex: ALL
Age: 15 Years to 70 Years
Study type: OBSERVATIONAL
Inclusion Criteria: Patients with RIS confirmed by the RIS expert center of the Nice CHU; EBNA status at RIS diagnosis available Exclusion Criteria: none
- Nice, France